Clinical trials: Cancer, Bladder
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Urinary Bladder Neoplasm
The Importance of Muscle Function in Patients With Disseminated Bladder Cancer
This study investigates if reduced muscle mass and muscle function predispose to poor completion of oncological treatment in patients with bladder cancer (including cancer of the renal pelvis, ureter and urethra) and if muscle…
- Trial name
- NCT04144270
- Testing
- Evaluation of muscle mass and muscle function
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Home-Based Supportive Care Program for NMIBC Patients Receiving Intravesical Perfusion: Construction and Preliminary Application
This study focuses on patients with non-muscle-invasive bladder cancer who receive intravesical perfusion therapy. Outpatient perfusion treatment is usually short-term and procedure-oriented, so patients often lack continuous…
- Trial name
- NMIBC-HSC (NCT07781956)
- Testing
- Supportive care program, Implementing routine urology outpatient infusion nursing
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Urinary Bladder Neoplasm
Holmium Versus Bipolar en Bloc Transurethral Resection of Urothelium Tumor of the Urinary Bladder
En bloc resection of bladder tumors (ERBT) may improve staging quality and perioperative morbidity and influence tumour recurrence
- Trial name
- NCT04576286
- Testing
- Holmium versus Bipolar en bloc transurethral resection
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Recurrent Bladder Cancer, Stage 0 Bladder Cancer
Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery
Rationale: Broccoli sprout extract contains ingredients that may prevent or slow the growth of certain cancers. Purpose: This pilot study is studying the side effects of broccoli sprout extract in treating patients with…
- Conditions
- Recurrent Bladder Cancer, Stage 0 Bladder Cancer, Stage I Bladder Cancer, Stage II Bladder Cancer
- Trial name
- NCT01108003
- Testing
- broccoli sprout extract, laboratory biomarker analysis, Mango Juice
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Roswell Park Cancer Institute
Bladder Cancer, Recurrent Bladder Cancer
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
Bladder cancer is the most common urinary tract cancer and the 6th most common cancer in the US. Yet bladder cancer research is underfunded relative to other common cancers.
- Conditions
- Bladder Cancer, Recurrent Bladder Cancer, Non-muscle Invasive Bladder Cancer (NMIBC)
- Trial name
- CISTO2 (NCT07225127)
- Where
- 6 sites in United States
- Volunteers
- 408 people
- Sponsor
- University of Washington
Bladder Cancer
Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer
A Comprehensive Geriatric Assessment (CGA) is a set of tests used to evaluate a patient's medical, social, and functional status, and can identify impairments in these domains that may not be noticed otherwise.
- Trial name
- NCT04273724
- Testing
- Targeted Interventions for Impairments Identified During Geriatric Assessment
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Muscle-Invasive Bladder Carcinoma
Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer
Bladder cancer (BC) is the 10th most commonly diagnosed cancer worldwide and the second most common cancer among Egyptian males.
- Trial name
- NCT06325423
- Testing
- neoadjuvant chemotherapy
- Volunteers
- 50 people
- Sponsor
- Assiut University
Bladder Cancer
Evaluation of Ultrasound Probe for Use in Bladder Radiotherapy
Muscle-invasive bladder cancer affects over 3,000 new patients in the UK each year and radiotherapy comprises a key part of the treatment pathway for many of them.
- Trial name
- NCT01698359
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University Hospital Birmingham NHS Foundation Trust
Bladder Cancer
A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy
The purpose of this study is to test if immunotherapy with nivolumab alone or in combination with ipilimumab is safe and does not delay the planned bladder cancer surgery.
- Trial name
- NCT03520491
- Testing
- Nivolumab, Ipilimumab, Radical cystectomy
- Where
- 7 sites in United States
- Volunteers
- 52 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer
Enzalutamide for Bladder Cancer Chemoprevention
The purpose of this study is to examine the effect of androgen deprivation therapy through administration of enzalutamide on preventing bladder cancer recurrences in patients with non-muscle invasive bladder cancer (NMIBC).
- Trial name
- NCT02605863
- Testing
- Enzalutamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Rochester
Urothelial Cancer
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic…
- Trial name
- NCT02603432
- Testing
- Avelumab, Best Supportive Care, Following the planned interim analysis for this study: Avelumab
- Where
- 382 sites in United States, Argentina and 27 more
- Volunteers
- 700 people
- Sponsor
- Pfizer
Non-muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
This is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients with BCG-unresponsive or BCG-exposed CIS NMIBC.
- Trial name
- ENHANCE (NCT06503614)
- Testing
- Durvalumab, Monalizumab
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- John Sfakianos
Bladder Neoplasms
Intravesical Chemotherapy Treatment of Superficial Bladder Cancer
This is a phase II study where chemotherapy (gemcitabine) is given into the urinary bladder.
- Trial name
- NCT00491114
- Testing
- Gemcitabine
- Where
- 7 sites in Italy
- Volunteers
- 8 people
- Sponsor
- Eli Lilly and Company
Urinary Bladder Cancer
Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer
To evaluate the feasibility, safety, and pathological response of dose-dense neoadjuvant gemcitabine and cisplatin in patients with muscle-invasive bladder cancer, with the goal of improving tumor downstaging and optimizing…
- Trial name
- No Acronym (NCT07184021)
- Testing
- Gemcitabine and Cisplatin (DD GC)
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
Bladder (Urothelial, Transitional Cell) Cancer
Evaluation of ENPP1 Expression and Immune Response in Bladder Cancer Patients
This study aims to investigate the role of ENPP1 in bladder cancer (BC), specifically focusing on its impact on immune evasion, chemoresistance, and prognosis.
- Trial name
- ENPP1-BC (NCT06657755)
- Testing
- Immunohistochemistry
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Lanzhou University Second Hospital
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Breast Cancer, Colorectal Cancer
Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- CDX1307-02 (NCT00648102)
- Testing
- CDX-1307
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
Breast Cancer, Melanoma
Immunological Variables Associated to ICI Toxicity in Cancer Patients
This is a monocentric, prospective, pilot study that will enrol 435 subjects with solid tumours that are treated with immune checkpoint inhibitor(s) (ICI) alone or in combination with chemotherapy or targeted therapy.
- Conditions
- Breast Cancer, Melanoma, Non Small Cell Lung Cancer, Non-melanoma Skin Cancer
- Trial name
- NCT05429866
- Testing
- Checkpoint Blockade, Immune
- Where
- Belgium
- Volunteers
- 441 people
- Sponsor
- Jules Bordet Institute
Bladder Cancer, Urinary Tract Cancer
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
Background: Urothelial cancer is cancer of the bladder, ureter, and urethra. Researchers want to better understand what changes in a person s cells and genes cause this cancer to form.
- Conditions
- Bladder Cancer, Urinary Tract Cancer, Urothelial Cancer, Healthy Volunteers
- Trial name
- NCT02379429
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.